Here are four notes:
1. On Feb. 8, Oppenheimer cut Zimmer Biomet’s price target to $120.
2. Following the price target reduction, the shares hit $90.75 per share, down nearly 4.5 percent.
3. Since July 2015, Zimmer Biomet’s shares have decreased 12.18 percent.
4. The shares have underperformed the S&P 500 by 2.71 percent.
More articles on devices:
FDA schedules meeting to review Cartiva’s PMA for synthetic cartilage implant: 4 points
Zimmer Biomet investors to offer 11M+ shares of common stock: 5 takeaways
Stryker director sells 12k shares, soon after Sage Products acquisition & potential Moody’s downgrade: 7 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
